Literature DB >> 9572492

p53 mutations isolated in yeast based on loss of transcription factor activity: similarities and differences from p53 mutations detected in human tumors.

C B Epstein1, E F Attiyeh, D A Hobson, A L Silver, J R Broach, A J Levine.   

Abstract

p53 is a transcriptional activator that plays a key role in the integration of signals inducing cell division arrest and programmed cell death. Moreover, p53 is a tumor suppressor gene, mutations of which are the most commonly detected mutations in diverse malignancies. In order to better understand the significance of p53 mutations to human cancer, we isolated mutant alleles of p53 that had lost transcription factor activity in yeast. These mutant alleles were evaluated for their precise changes, their activity against three different p53 responsive enhancers and their ability to act in a transdominant fashion to the wild type allele. While many of the mutations isolated in yeast resembled those found in human tumors, consistent with the importance of transcription factor activity for p53 in mammalian cells, the mutational spectrum obtained was dependent upon the p53 enhancer employed for the selection. Some mutations specifically inactivated p53 in yeast for a single enhancer element. Virtually all missense mutations tested had a dominant inhibitory effect on wild type p53 in yeast. Since some of these transdominant mutations are virtually unknown in human tumors we conclude that transdominance, per se, fails to predict which mutations occur frequently in cancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9572492     DOI: 10.1038/sj.onc.1201734

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

1.  Identification of partial loss of function p53 gene mutations utilizing a yeast-based functional assay.

Authors:  G K Kovvali; B Mehta; C B Epstein; S G Lutzker
Journal:  Nucleic Acids Res       Date:  2001-03-01       Impact factor: 16.971

2.  Histone deacetylase-dependent transcriptional repression by pRB in yeast occurs independently of interaction through the LXCXE binding cleft.

Authors:  B K Kennedy; O W Liu; F A Dick; N Dyson; E Harlow; M Vidal
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-10       Impact factor: 11.205

3.  NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53.

Authors:  Marie Zbinden; Arnaud Duquet; Aiala Lorente-Trigos; Sandra-Nadia Ngwabyt; Isabel Borges; Ariel Ruiz i Altaba
Journal:  EMBO J       Date:  2010-06-25       Impact factor: 11.598

4.  AP4 activates cell migration and EMT mediated by p53 in MDA-MB-231 breast carcinoma cells.

Authors:  Shaopeng Chen; Sung-Kay Chiu
Journal:  Mol Cell Biochem       Date:  2015-06-03       Impact factor: 3.396

5.  An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival.

Authors:  Lance D Miller; Johanna Smeds; Joshy George; Vinsensius B Vega; Liza Vergara; Alexander Ploner; Yudi Pawitan; Per Hall; Sigrid Klaar; Edison T Liu; Jonas Bergh
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-02       Impact factor: 11.205

6.  p53 downregulates its activating vaccinia-related kinase 1, forming a new autoregulatory loop.

Authors:  Alberto Valbuena; Francisco M Vega; Sandra Blanco; Pedro A Lazo
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

7.  Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44.

Authors:  Chandi Charan Mandal; Nayana Ghosh-Choudhury; Toshi Yoneda; Goutam Ghosh Choudhury; Nandini Ghosh-Choudhury
Journal:  J Biol Chem       Date:  2011-01-03       Impact factor: 5.157

8.  Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial.

Authors:  Chih-Jian Lih; David J Sims; Robin D Harrington; Eric C Polley; Yingdong Zhao; Michele G Mehaffey; Thomas D Forbes; Biswajit Das; William D Walsh; Vivekananda Datta; Kneshay N Harper; Courtney H Bouk; Lawrence V Rubinstein; Richard M Simon; Barbara A Conley; Alice P Chen; Shivaani Kummar; James H Doroshow; Paul M Williams
Journal:  J Mol Diagn       Date:  2015-11-18       Impact factor: 5.568

9.  Mutant p53-associated myosin-X upregulation promotes breast cancer invasion and metastasis.

Authors:  Antti Arjonen; Riina Kaukonen; Elina Mattila; Pegah Rouhi; Gunilla Högnäs; Harri Sihto; Bryan W Miller; Jennifer P Morton; Elmar Bucher; Pekka Taimen; Reetta Virtakoivu; Yihai Cao; Owen J Sansom; Heikki Joensuu; Johanna Ivaska
Journal:  J Clin Invest       Date:  2014-03       Impact factor: 14.808

10.  Mutant p53 induces EZH2 expression and promotes epithelial-mesenchymal transition by disrupting p68-Drosha complex assembly and attenuating miR-26a processing.

Authors:  Fei-Zhou Jiang; Yin-Yan He; Hui-Hui Wang; Hui-Lin Zhang; Jian Zhang; Xiao-Fang Yan; Xiao-Jun Wang; Qi Che; Jie-Qi Ke; Zheng Chen; Huan Tong; Yong-Li Zhang; Fang-Yuan Wang; Yi-Ran Li; Xiao-Ping Wan
Journal:  Oncotarget       Date:  2015-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.